SPRUSS, T and BERNHARDT, G and SCHONENBERGER, H and ENGEL, J (1993) ANTITUMOR-ACTIVITY OF MILTEFOSINE ALONE AND AFTER COMBINATION WITH PLATINUM COMPLEXES ON MXT MOUSE MAMMARY-CARCINOMA MODELS. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 119 (3). pp. 142-149. ISSN 0171-5216,
Full text not available from this repository.Abstract
Miltefosine, an alkylphosphocholine structurally related to alkyllysophospholipids showed highly selective antitumour activity against the hormone-sensitive variant of the s.c. transplantable MXT mouse mammary adenocarcinoma, the ovary-dependent MXT (M3.2), whereas it was inactive against the hormone-insensitive MXT (M3.2) OVEX variant. A dose of 32 mg/kg miltefosine p.o. daily for 5 weeks was well tolerated. Histopathological evaluation gave no signs of gastroenteral toxicity. After therapy the microarchitecture of the MXT (M3.2) tumours changed from that of a moderately differentiated adenocarcinoma to that of an anaplastic mammary carcinoma. A dose of 16 mg/kg miltefosine p.o. daily, though in effective per se, enhanced the antitumour activity of suboptimal i.p. doses of cisplatin and the hormone-like platinum analogue [meso-1,2-bis(2.6-dichloro-4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II). Furthermore, it was shown, that miltefosine exhibited no (anti)hormonal properties. However, the mechanism of action of miltefosine remains unclear.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | PROTEIN-KINASE-C; MYELOID-LEUKEMIA CELLS; ALKYL-LYSOPHOSPHOLIPIDS; TUMOR; HEXADECYLPHOSPHOCHOLINE; DIFFERENTIATION; INHIBITION; PHOSPHOLIPIDS; INDUCTION; MILTEFOSINE; CISPLATIN ANALOGS; MXT MOUSE MAMMARY TUMORS; COMBINATION THERAPY |
| Depositing User: | Dr. Gernot Deinzer |
| Last Modified: | 19 Oct 2022 08:43 |
| URI: | https://pred.uni-regensburg.de/id/eprint/54195 |
Actions (login required)
 |
View Item |
